We are live on ! Find out more
QTTB icon

Q32 Bio
QTTB

61 hedge funds and large institutions have $13.4M invested in Q32 Bio in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

3.5% less ownership

Funds ownership: 77.11% → 73.61% (-3.5%)

14% less capital invested

Capital invested by funds: $15.5M → $13.4M (-$2.16M)

16% less funds holding

Funds holding: 73 → 61 (-12)

37% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 19

55% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 22

Holders
61
Holders Change
-12
Holders Change %
-16.44%
% of All Funds
0.8%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.05%
New
10
Increased
12
Reduced
19
Closed
22
Calls
$19K
Puts
–
Net Calls
+$19K
Net Calls Change
+$26K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$222K
2
MAM
Monaco Asset Management
Monaco
+$147K
3
Renaissance Technologies
Renaissance Technologies
New York
+$131K
4
Jane Street
Jane Street
New York
+$79.5K
5
Goldman Sachs
Goldman Sachs
New York
+$32.7K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$475K
2
State Street
State Street
Massachusetts
-$188K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$129K
4
Mariner
Mariner
Kansas
-$124K
5
N
Nuveen
North Carolina
-$92.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$3.36M – – –
AVLSA
2
Atlas Venture Life Science Advisors
Massachusetts
$3.12M – – –
CG
3
Carlyle Group
District of Columbia
$1.62M – – –
ACA
4
Acorn Capital Advisors
New York
$1.2M – – –
MAM
5
Monaco Asset Management
Monaco
$882K +$147K +86,486 +17%
AVM
6
Arch Venture Management
Illinois
$478K – – –
P
7
Pfizer
New York
$414K – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$401K -$67.8K -39,785 -13%
S
9
Sanofi
France
$364K – – –
BlackRock
10
BlackRock
New York
$266K -$475K -278,694 -61%
TOCUITCONY
11
Trustees of Columbia University in the City of New York
New York
$200K – – –
Millennium Management
12
Millennium Management
New York
$194K +$222K +130,379 New
Renaissance Technologies
13
Renaissance Technologies
New York
$115K +$131K +77,000 New
Goldman Sachs
14
Goldman Sachs
New York
$94.7K +$32.7K +19,166 +43%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$91.8K -$129K -75,910 -55%
Jane Street
16
Jane Street
New York
$69.5K +$79.5K +46,635 New
Fidelity Investments
17
Fidelity Investments
Massachusetts
$63.2K -$34K -19,952 -32%
Acadian Asset Management
18
Acadian Asset Management
Massachusetts
$44K -$2.38K -1,399 -4%
AAA
19
Affinity Asset Advisors
New York
$41.4K – – –
State Street
20
State Street
Massachusetts
$40.1K -$188K -110,561 -80%
AQR Capital Management
21
AQR Capital Management
Connecticut
$39.5K -$25.2K -14,772 -36%
Northern Trust
22
Northern Trust
Illinois
$38.8K -$58.1K -34,076 -57%
Morgan Stanley
23
Morgan Stanley
New York
$27.8K +$6.8K +3,991 +27%
Marshall Wace
24
Marshall Wace
United Kingdom
$25.2K +$28.9K +16,928 New
OC
25
Oppenheimer & Co
New York
$19.4K +$22.2K +13,000 New
1
2 3 4

QTTB Hedge Fund Activity: Q2 2025 in Review

61 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q2 2025, worth a combined $13.4M — down 14% from $15.5M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of QTTB and 10 opened new positions — a net loss of 12 holders — while 19 trimmed existing stakes and 12 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $222K. The largest seller was BlackRock, cutting an estimated $475K.

  • 61 institutional investors held Q32 Bio (QTTB) as of Q2 2025, down from 73 in Q1 2025.
  • Funds reported $13.4M of Q32 Bio stock for Q2 2025, down 14% quarter-over-quarter.
  • 10 funds opened new Q32 Bio positions in Q2 2025 and 22 closed out, a net change of -12 holders.
  • The largest Q32 Bio buyer in Q2 2025 was Millennium Management, an estimated $222K added.
  • The largest Q32 Bio seller in Q2 2025 was BlackRock, an estimated $475K sold.

Based on aggregated 13F filings for Q2 2025.